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SuMMAry – recently, studies have reported that inflammatory response and elevated platelet 
counts are associated with several cancers. in the present study, we aimed to evaluate hemocytometer 
parameters in differentiating adrenal adenoma and carcinoma, and the prognostic utility of hemocy-
tometer parameters in adrenocortical carcinoma (ACC). we included 30 patients with nonfunctional 
adrenal adenoma and 13 patients with ACC having undergone surgery between 2005 and 2017 and 
followed up postoperatively at our centre. The neutrophil/lymphocyte ratio (nlr), platelet/lympho-
cyte ratio (Plr), red blood cell distribution width (rdw), mean platelet volume (MPV) and platelet-
crit (PCt) were evaluated preoperatively in all patients included in the study. There was a significant 
difference between the adrenal adenoma and ACC groups in terms of neutrophil and lymphocyte 
counts, nlr and Plr. There was no significant difference between the two groups in terms of plate-
let count and MPV, but PCt levels were significantly lower in ACC group. There was no statistically 
significant difference between recurrent and/or metastasis positive patients and negative ones accord-
ing to nlr, Plr, rdw and MPV. There was a statistically significant difference in rdw levels and 
tumor diameter between the groups. Our study is the first to evaluate hemocytometer parameters in 
differentiating adrenal adenomas and carcinomas, and also in the prognosis of ACC. The present study 
suggested that the hemocytometer parameters may be a marker in the differential diagnosis of adrenal 
adenomas and carcinomas. however, our study also showed that these parameters had no prognostic 
value in ACC.
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Introduction
Adrenal incidentaloma is defined as an asymptom-
atic adrenal mass detected on imaging not performed 
for suspected adrenal disease. Adrenal incidentalomas 
are composed of benign and malignant lesions, and 
benign adenomas constitute more than 90% of adrenal 
incidentalomas1. Adrenocortical carcinoma (ACC) is a 
rarely seen endocrine malignancy and diagnosis is 
generally established based on symptoms due to hy-
persecretion from tumor or local effects of large tumor 
lesions. recently, ACC is mostly detected in the as-
ymptomatic period owing to the increasing utilization 
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of imaging methods2. when adrenal mass is detected 
on imaging, it is recommended to establish whether 
the adrenal mass is benign or malignant. for this pur-
pose, performing computed tomography (Ct) may be 
recommended. taking biopsy material from the mass 
is not recommended due to the risk of implantation of 
tumor cells into the surrounding tissues. until now, no 
biochemical parameter clearly indicating whether an 
adrenal mass is benign or malignant has been identi-
fied3.
recently, the relationship between some of the he-
mocytometer parameters and cancer has been investi-
gated4. The neutrophil/lymphocyte ratio (nlr), plate-
let/lymphocyte ratio (Plr), red blood cell distribution 
width (rdw) and mean platelet volume (MPV) are 
the most studied parameters5. Platelets play a pivotal 
role in many steps of cancer development, such as tu-
mor growth, invasion, aberrant angiogenesis, and me-
tastasis due to the interaction with tumor cells6. Plate-
lets are rich in growth factors including platelet-derived 
growth factor and transforming growth factor-β. These 
factors are often produced by tumor cells and contrib-
ute to tumor progression7. elevated platelets have been 
shown to be associated with poor prognosis in several 
cancers including gastric cancer, colorectal cancer, pan-
creatic cancer and gynecologic cancers. Since total 
platelet count depends on the balance between platelet 
production and consumption, platelet volume indices 
are more frequently used8. MPV, the most commonly 
used measure of platelet size, is an indicator of activated 
platelets. Altered MPV levels were found in a wide 
range of cancers such as gastric cancer, colon cancer, 
lung cancer, breast cancer and ovarian cancer7.
The relationship between inflammation and malig-
nancies has been known for years. inflammation plays 
a role in cancer proliferation, angiogenesis and inva-
sion. Since nlr is a biomarker of inflammation, many 
recent studies have shown an association between 
nlr and various types of cancer4,9. in the present 
study, we aimed to evaluate hemocytometer parame-
ters in differentiating adrenal adenoma and carcinoma, 
and the prognostic utility of hemocytometer parame-
ters in ACC.
Patients and Methods
The study included 13 ACC patients and 30 pa-
tients with nonfunctional adrenal adenoma having un-
dergone surgery during the 2005-2017 period, with 
postoperative follow up at our centre. All study pa-
tients were evaluated for Cushing syndrome, primary 
hyperaldosteronism and pheochromocytoma. Cushing 
syndrome was diagnosed in patients with serum corti-
sol >1.8 µg/dl following 1 mg dexamethasone sup-
pression test or 2 days of low-dose dexamethasone 
suppression test and in patients with suppressed serum 
adrenocorticotropic hormone (ACth) levels (<5 pg/
ml). hyperaldosteronism was excluded if the plasma 
renin activity (PrA)/aldosterone ratio was <30. Simi-
larly, pheochromocytoma was excluded in patients 
with normal plasma metanephrine and normetaneph-
rine levels. Patients with Cushing syndrome, hyperal-
dosteronism and pheochromocytoma were excluded. 
The study was approved by the institutional ethics 
Committee. data on age, sex, preoperative biochemi-
cal testing and radiological imaging results of the pa-
tients included in the study were obtained from pa-
tient files. Preoperative Ct was used to assess adrenal 
mass diameter based on the shortest and longest diam-
eters. in addition, archival files of ACC patients were 
reviewed and data on tumor diameter on pathologic 
examination studied. tumor diameter was evaluated 
based on the long and short diameters on postopera-
tive pathologic examination. in patients with ACC, 
data were also collected on recurrence and metastasis 
development during postoperative follow up.
Patients were divided into groups with adrenal ad-
enomas and carcinomas. The latter were further divid-
ed into two subgroups of patients with and without 
recurrence/metastasis. hemoglobin, hematocrit, neu-
trophils, lymphocytes, platelet count, nlr, Plr, 
rdw, platelet distribution width (Pdw), MPV and 
plateletcrit (PCt) performed in the last five days be-
fore operation were evaluated in all patients included 
in the study. The PCt = platelet count x MPV/10000 
formula was used for PCt calculation10.
Statistical analysis
Statistical evaluations were performed using ibM 
SPSS version 21 (ibM Acquires SPSS inc., Somers, 
ny, uSA). The χ2-test was used for comparison of cat-
egorical data, whereas the Mann-whitney u test or 
Student’s t-test was used for comparison of numerical 
data, as appropriate. Spearman correlation analysis was 
applied for correlation analyses. demographic charac-
teristics and preoperative frequency data were ex-
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pressed as mean and standard deviation (Sd) and per-
cent (%) where appropriate. A p value <0.05 was con-
sidered statistically significant.
Results
A total of 43 patients, 30 patients with nonfunc-
tional adrenal adenomas and 13 patients with ACC, 
were included in the study. There were 27 (62.7%) fe-
male and 16 (37.3%) male patients, mean age at diag-
nosis 53.5±11.4 years. demographic characteristics of 
the patients are shown in table 1.
Of the 30 patients with adrenal adenoma included 
in the study, there were seven (23.3%) male and 23 
(76.7%) female patients, mean age at diagnosis 
53.0±11.2 years. The mean longest tumor diameter was 
33.6±13.8 mm and 38.2±20.7 mm recorded on preop-
erative radiological evaluation and postoperative 
pathologic examination of patients, respectively. Of 
the 13 patients with ACC included in the study, there 
were nine (69.2%) male and four (30.8%) female pa-
tients, mean age at diagnosis 54.61±12.16 years. The 
mean longest tumor diameter was 73.4±51.1 mm on 
preoperative radiological evaluation and 80.3±55.8 
mm on postoperative pathologic examination.
There was no significant age difference between 
adrenal adenoma and ACC groups. hemoglobin and 
hematocrit levels were statistically lower and rdw 
levels higher in patients with ACC. however, there 
was no significant difference according to rbC level 
between the two groups. The mean neutrophil level 
was 5577±3287 k/µl in the adrenal adenoma group 
and 7452±2396 k/µl in the ACC group. The mean 
lymphocyte level was 2498±1179 k/µl and 
1420±0.687 k/µl in the adrenal adenoma and ACC 
group, respectively. There was a significant between-
group difference according to neutrophil, lymphocyte, 
nlr and Plr values. in our study, platelet count, 
MPV and PCt were also compared between the two 
groups. There was no significant between-group differ-
ence according to platelet count and MPV, but PCt 
levels were significantly lower in the ACC group.
during follow up, locoregional recurrence was ob-
served in one patient, distant metastasis in two pa-
tients, and both locoregional recurrence and distant 
metastasis were observed in two patients. nlr, Plr, 
rdw and MPV values were 4.10±1.45, 204.77±70.76, 
17.46±1.38 and 7.74±0.73 in patients with recurrent 
and/or metastatic disease, respectively. in patients 
without recurrence and/or metastasis, nlr, Plr, 
rdw and MPV values were 9.24±6.74, 232.62±135.97, 
15.98±1.47 and 8.85±1.18, respectively. There was no 
statistically significant difference according to nlr, 
Plr, rdw and MPV between recurrent and/or me-
tastasis positive patients and negative ones. There was 
a statistically significant difference in rdw levels and 








diagnosis (yrs) 53.0±11.2 54.6±12.1 0.62
Sex:
Male (%) 7 (23.3) 9 (69.2)
0.007
female (%) 23 (76.7) 4 (30.8)
neutrophil 
count (k/µl) 5577±3287 7452±2396 0.03
lymphocyte 
count (k/µl) 2498±1179 1420±0.687 0.001
Platelet count 









rdw (%) 14.8±1.7 16.5±1.5 0.006
MPV (fl) 8.5±1.7 8.4±1.1 0.83
PCt (%) 0.22±0.05 0.17±0.02 0.01
Pdw (%) 17.1±1.2 17.0±1.8 0.95
hemoglobin 
(g/dl) 13.3±1.4 12.1±1.7 0.03
hematocrit 





rbC (M/µu) 4.5±0.5 4.3±0.6 0.25
wbC (k/µl) 8.6±3.2 8.5±2.5 0.98
rdw = red blood cell distribution width; MPV = mean platelet 
volume; PCt = plateletcrit; Pdw = platelet distribution width; 
rbC = red blood cell; wbC = white blood cell
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tumor diameter between the two groups (p=0.007) 
(table 2).
Discussion
Adrenal incidentaloma is defined as a mass detect-
ed in the adrenal gland on an imaging study performed 
for other reasons unrelated to adrenal disease. The 
prevalence of adrenal incidentaloma increases with age 
and is seen at an equal frequency in male and female 
individuals. The prevalence of adrenal incidentaloma is 
about 4% in the middle age group and ACC accounts 
for approximately 8% of all adrenal incidentalomas. 
when adrenal incidentaloma is found, determination 
of excess adrenal hormone hypersecretion and assess-
ment of the possible tumor malignancy is suggested11.
imaging modalities such as Ct, magnetic reso-
nance imaging (Mri) and 18f-fdg-Pet are mostly 
preferred to differentiate benign and malignant tu-
mors of the adrenal gland12. The majority of adrenal 
adenomas contain high fat. however, malignant adre-
nal lesions contain almost no fat. hounsfield unit 
(hu) on non-contrast Ct has high sensitivity and 
specificity in differentiating benign and malignant le-
sions. The pattern obtained after contrast enhance-
ment (called washout) is also a good way to distinguish 
between benign and malignant tumors13. Adenomas 
demonstrate low attenuation on unenhanced Ct (≤10 
hu) and absolute enhancement washout of contrast 
≥60% and/or relative washout ≥40% on contrast en-
hanced Ct. losing of signal in opposed-phased Mri 
is also diagnostic of adenoma14. unenhanced measure-
ments >30 hu on Ct usually indicate ACC or pheo-
chromocytoma. large tumor size, heterogeneous en-
hancement, necrosis and invasion of adjacent organs 
are other features suggesting malignancy15.
Adrenocortical carcinomas are usually large (>6 
cm), heterogeneous and aggressive tumors with necro-
sis, hemorrhage and calcifications in 30% of cases. re-
currence rate of ACC after surgery is high and prog-
nosis is poor even in non-metastatic cases16. it is gen-
erally not possible to distinguish malignant tumors 
based only on clinical features. There is no well-known 
biochemical parameter predicting malignancy either. 
fine needle aspiration biopsy is not useful in differen-
tiating between adrenal adenoma and primary adrenal 
carcinoma11. besides, in case of suspected ACC, fine 
needle aspiration biopsy should not be performed due 
to the risk of tumor spillage. it may be used to evaluate 
an indeterminate adrenal mass with a known primary 
tumor17. in our study, the mean longest diameter of 
tumors was 38.2±20.7 mm on postoperative patho-
logic examination in patients with adrenal adenoma. 
in the ACC group, pathologic examination showed a 
mean diameter of 80.3±55.8 mm.
Measuring the hemocytometer parameters is a rela-
tively inexpensive and universally available method. its 
implementation is easy and results are obtained quickly7. 
in recent years, it has been shown that hemostatic pa-
rameters may be beneficial both in benign-malignant 
differential diagnosis and in cancer prognosis4. in the 
study conducted by Cui et al., reduced Pdw was dem-
onstrated to be independently associated with prognosis 
of non-small cell lung cancer8. in another study, the re-
lationship between MPV and clinicopathological char-
acteristics of colorectal cancer was evaluated, demon-
strating that MPV was elevated in colorectal cancer18. 
gaitanidis et al. also showed Plr and MPV to be inde-
pendent predictors of disease progression in pancreatic 
neuroendocrine tumors19. Similar to previous literature 
reports, takeuchi et al. demonstrated that elevated 
Pdw/platelet count significantly reduced disease-free 
survival in patients with breast cancer7. in our study, 
there was no significant difference between the adrenal 
adenoma and ACC groups according to platelet count 
and MPV, but PCt levels were significantly lower in 
the ACC group. Our results also showed that there was 
no statistically significant difference according to MPV 
levels between recurrence and/or metastasis positive pa-
tients and negative ones.
Table 2. Comparison of hematologic parameters according 









diagnosis (yrs) 55.40±11.30 54,12±13.42 1.00
gender, M/f 3/2 1/7
nlr 4.10±1.45 9.24±6.74 0.50
Plr 204.77±70.76 232.62±135.97 0.77
rdw (%) 17.46±1.38 15.98±1.47 0.09
MPV 7.74±0.73 8.85±1.18 1.10
nlr = neutrophil/lymphocyte ratio; Plr = platelet/lymphocyte 
ratio; rdw = red blood cell distribution width; MPV = mean 
platelet volume
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Since inflammation plays a role in several steps of 
the carcinogenesis process, in recent years, nlr and 
Plr have been evaluated in various types of cancer9. 
Miyamoto et al. found preoperative nlr to be a useful 
predictor of both long-term and short-term outcomes 
in gastric cancer patients20. in a meta-analysis that in-
cluded 8252 patients, nlr was found to be a promis-
ing prognostic biomarker for pancreatic cancer21. in 
another meta-analysis including 3028 patients, li et al. 
have reported elevated Plr to be associated with un-
favorable overall survival in pancreatic cancer22. rdw 
is also found as a strong predictor of all-cause mortal-
ity and cancer progression in prostate cancer23.
On the other hand, yaylacı et al. did not find any 
significant relationship between benign nodular goiter 
and papillary thyroid carcinoma in terms of nlr and 
MPV24. in addition to the contradictory results of pre-
vious studies, Ozyalvaclı and yasar report on a multi-
tude of factors affecting standardization of MPV mea-
surement, such as blood drawing by venipuncture, type 
and amount of anticoagulant in the blood collection 
tube, and time elapsed from blood drawing to testing25. 
in our study, there were significant differences between 
the patients with adrenal adenomas and ACC accord-
ing to neutrophil, lymphocyte, nlr and Plr. how-
ever, when nlr and Plr were compared between 
recurrent and/or metastasis positive patients and nega-
tive ones, no significant difference was found.
because the majority of adrenal masses are benign 
adenomas, identification of novel markers for use in 
the preoperative period to determine whether suspect-
ed adrenal masses are benign or malignant is impor-
tant. The limitations of the present study were the 
small number of patients and the single-centre study 
design. The retrospective nature of the study may also 
be considered as a limitation of the study. despite 
these limitations, our study was the first to evaluate 
hemocytometer parameters in differentiating adrenal 
adenomas and carcinomas, as well as its potential role 
in the prognosis of ACC.
According to many studies in the literature, nlr, 
Plr, rdw and MPV seem to be associated with 
poor outcomes in various types of cancer. however, the 
studies investigating these markers are very heteroge-
neous and there are a number of studies advocating 
countervailing opinion. The present study suggested 
that the hemocytometer parameters may be a marker 
in the differential diagnosis of adrenal adenomas and 
carcinomas. however, our study also showed that these 
parameters were not useful in the prognosis of ACC. 
we think that more comprehensive studies in larger 
patient series may reveal the significance of these pa-
rameters in the diagnosis and prognosis of ACC more 
clearly and definitely.
References
 1. Sahdev A. recommendations for the management of adrenal 
incidentalomas: what is pertinent for radiologists? br J radiol. 
2017;90(1072):20160627. doi: 10.1259/bjr.20160627. epub 
2017 feb 9.
 2. Şişman P, Şahin Ab, Peynirci h, Cander S, gül ÖÖ, ertürk e, 
ersoy C. Adrenocortical carcinoma: single center experience. 
turk J urol. 2017;43(4):462-9.
 3. fassnacht M, Arlt w, bancos i, dralle h, newell-Price J, Sah-
dev A, tabarin A, terzolo M, tsagarakis S, dekkers OM. 
Management of adrenal incidentalomas: european Society of 
endocrinology Clinical Practice guideline in collaboration 
with the european network for the Study of Adrenal tumors. 
eur J endocrinol. 2016 Aug;175(2):g1-g34. doi: 10.1530/
eJe-16-0467.
 4. goh bk, Chok Ay, Allen JJ, Quek r, teo MC, Chow Pk, et al. 
blood neutrophil-to-lymphocyte and platelet-to-lymphocyte 
ratios are independent prognostic factors for surgically resected 
gastrointestinal stromal tumors. Surgery. 2016;159:1146-56.
 5. berger JS, eraso lh, Xie d, Sha d, Mohler er. Mean platelet 
volume and prevalence of peripheral artery disease, the na-
tional health and nutrition examination Survey, 1999-2004. 
Atherosclerosis. 2010;213:586-91.
 6. bambace nM, holmes Ce. The platelet contribution to cancer 
progression. J Thromb haemost. 2011;9(2):237-49.
 7. takeuchi h, Abe M, takumi y, hashimoto t, kobayashi r, 
Osoegawa A, Miyawaki M, Okamoto t, Sugio k. The prognos-
tic impact of the platelet distribution width-to-platelet count 
ratio in patients with breast cancer. PloS One. 2017 dec 
7;12(12):e0189166. doi: 10.1371/journal.pone.0189166. eCol-
lection 2017.
 8. Cui MM, li n, liu X, yun Zy, niu y, Zhang y, gao b, liu t, 
wang rt. Platelet distribution width correlates with prognosis 
of non-small cell lung cancer. Sci rep. 2017 Jun 14;7(1):3456. 
doi: 10.1038/s41598-017-03772-z.
 9. Zhang J, Zhang hy, li J, Shao Xy, Zhang CX. The elevated 
nlr, Plr and Plt may predict the prognosis of patients with 
colorectal cancer: a systematic review and meta-analysis. Onco-
target. 2017;8(40):68837-46. doi: 10.18632/oncotarget.18575. 
eCollection 2017 Sep 15.
10. giacomini A, legovini P, gessoni g, Antico f, Valverde S, Sal-
vadego MM, et al. Platelet count and parameters determined by 
the bayer AdViA 120 in reference subjects and patients. Clin 
lab haematol 2001;23:181-6.
11. lee JM, kim Mk, ko Sh, koh JM, kim by, kim Sw, et al. 
Clinical guidelines for the management of adrenal inciden-
taloma. endocrinol Metab. 2017;32(2):200-18.
Pinar Sisman et al. Hemocytometer parameters in adrenal adenomas and carcinomas
444 Acta Clin Croat, Vol. 59, No. 3, 2020
12. kanagarajah P, Ayyathurai r, Manoharan M, narayanan g, 
kava br. Current concepts in the management of adrenal in-
cidentalomas. urol Ann. 2012;4:137-44.
13. Zeiger MA, Siegelman SS, hamrahian Ah. Medical and sur-
gical evaluation and treatment of adrenal insidentalomas. J Clin 
endocrinol Metab. 2011;96:2004-15.
14. wale dJ, kit wong k, Viglianti Vl, rubellop d, gross Md. 
Contemporary imaging of incidentally discovered adrenal 
masses. biomed Pharmocother. 2017;87:256-62.
15. fergany Af. Adrenal masses: a urological perspective. Arab J 
urol. 2016;14(4):248-55.
16. terzolo M, Angeli A, fassnacht M, daffara f, tauchmanova l, 
Conton PA, rossetto r, buci l, Sperone P, grossrubatscher e, 
reimondo g, bollito e, Papotti M, Saeger w, hahner S, 
koschker AC, Arvat e, Ambrosi b, loli P, lombardi g, Man-
nelli M, bruzzi P, Mantero f, Allolio b, dogliotti l, berruti A. 
Adjuvant mitotane treatment for adrenocortical carcinoma. n 
engl J Med. 2007;356(23):2372-80.
17. bhat hS, tiyadath bn. Management of adrenal masses. indi-
an J Surg Oncol. 2017;8(1):67-73.
18. li n, Zhiwei yu, Zhang X, lu t, Sun yX, wang rt, yu kJ. 
elevated mean platelet volume predicts poor prognosis in 
colorectal cancer. Sci rep. 2017;7(1):10261. doi: 10.1038/
s41598-017-11053-y.
19. gaitanidis A, Patel d, nilubol n, tirosh A, Sadowski S, kebe-
bew e. Markers of systemic inflammatory response are prog-
nostic factors in patients with pancreatic neuroendocrine tu-
mors (Pnets): a retrospective analysis. Ann Surg Oncol. 2018 
Jan;25(1):122-30. doi: 10.1245/s10434-017-6241-4. epub 
2017 nov 13.
20. Miyamoto r, inagawa S, Sano n, tadano S, Adachi S, yama-
moto M. The neutrophil-to-lymphocyte ratio (nlr) predicts 
short-term and long-term outcomes in gastric cancer patients. 
eur J Surg Oncol. 2018; feb 13. pii: S0748-7983(18)30296-8. 
doi: 10.1016/j.ejso.2018.02.003.
21. Zhou y, wei Q, fan J, Cheng S, ding w, hua Z. Prognostic 
role of the neutrophil-to-lymphocyte ratio in pancreatic can-
cer: a meta-analysis containing 8252 patients. Clin Chim Acta. 
2018 Apr;479:181-9. doi: 10.1016/j.cca.2018.01.024. epub 
2018 feb 2.
22. li w, tao l, lu M, Xiu d. Prognostic role of platelet to lym-
phocyte ratio in pancreatic cancers: a meta-analysis including 
3028 patients. Medicine (baltimore). 2018 feb;97(8):e9616. 
doi: 10.1097/Md.0000000000009616.
23. Albayrak S, Zengin k, tanik S, bakirtas h, imamoglu A, gurdal 
M. red cell distribution width as a predictor of prostate cancer 
progression. Asian Pac J Cancer Prev. 2014;15(18):7781-4.
24. yaylaci S, tosun O, Sahin O, genc Ab, Aydin e, demiral g, et 
al. lack of variation in inflammatory hematological parameters 
between benign nodular goiter and papillary thyroid cancer. 
Asian Pac J Cancer Prev. 2016;17:2321-3.
25. Ozyalvaclı g, yasar Z. is MPV a real prognostic indicator for 
non-small cell lung cancer? Asian Pac J Cancer Prev. 2014;15 
(18):8003.
Sažetak
MOgu li heMOCitOMetriJSki PArAMetri POSluŽiti kAO biOlOŠki bilJeZi  
u rAZlikOVAnJu AdrenAlnih AdenOMA i kArCinOMA  
te u PrOgnOZi AdrenOkOrtikAlnih kArCinOMA?
P. Sisman, B. Bicer, O. oz Gul, S. Cander, C. Ersoy, O. Saraydaroglu i E. Erturk
nedavna istraživanja pokazuju da su upalni odgovor i povišeni trombociti udruženi s nekim vrstama karcinoma. Cilj 
našega istraživanja bio je procijeniti hemocitometrijske parametre u razlikovanju adrenalnog adenoma i karcinoma, kao i 
prognostičku vrijednost hemocitometrijskih parametara u adrenokortikalnom karcinomu (adrenocortical carcinoma, ACC). u 
istraživanje smo uključili 30 bolesnika s nefunkcionalnim adrenalnim adenomom i 13 bolesnika s ACC operiranih između 
2005. i 2017. godine i poslije operacije praćene u našoj ustanovi. kod svih bolesnika uključenih u studiju prijeoperacijski su 
izmjereni sljedeći parametri: omjer neutrofila i limfocita (neutrophil/lymphocyte ratio, nlr), omjer trombocita i limfocita 
(platelet/lymphocyte ratio, Plr), širina distribucije eritrocita (red blood cell distribution width, rdw), srednji volumen trom-
bocita (mean platelet volume, MPV) i pleteletkrit (PCt). utvrđena je statistički značajna razlika između skupina bolesnika s 
adrenalnim adenomom i onih s ACC u broju neutrofila i limfocita, nlr i Plr. nije bilo značajne razlike među skupinama 
u broju trombocita i MPV, ali su razine PCt bile značajno niže u skupini s ACC. nije bilo statistički značajne razlike u nlr, 
Plr, rdw i MPV između bolesnika s opetovanim ACC i/ili metastazama i onih bez tih stanja. Statistički značajna razlika 
između skupina nađena je za razine rdw i promjer tumora. naše istraživanje je prvo te vrste u kojem su se procjenjivali 
hemocitometrijski parametri u razlikovanju adrenalnih adenoma i karcinoma te u prognozi ACC. rezultati studije ukazuju 
na to da bi se hemocitometrijski parametri mogli primijeniti kao biljezi u diferencijalnoj dijagnostici adrenalnih adenoma i 
karcinoma. Međutim, naše je istraživanje pokazalo kako ovi parametri nemaju prognostičku vrijednost kod ACC.
ključne riječi: Adrenalni adenom; Adrenokortikalni karcinom; Hemocitometrijski parametri; Srednji volumen trombocita; 
Omjer neutrofila i limfocita
